ADMA Biologics, Inc.
ADMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4,397,546 | $4,717,456 | $4,054,843 |
| - Cash | $61,385 | $90,285 | $71,625 | $103,147 |
| + Debt | $79,481 | $83,825 | $82,013 | $82,116 |
| Enterprise Value | – | $4,391,086 | $4,727,844 | $4,033,812 |
| Revenue | $134,224 | $121,984 | $114,802 | $117,549 |
| % Growth | 10% | 6.3% | -2.3% | – |
| Gross Profit | $75,626 | $67,227 | $61,097 | $63,333 |
| % Margin | 56.3% | 55.1% | 53.2% | 53.9% |
| EBITDA | $51,213 | $43,989 | $37,394 | $39,536 |
| % Margin | 38.2% | 36.1% | 32.6% | 33.6% |
| Net Income | $36,428 | $34,219 | $26,904 | $111,896 |
| % Margin | 27.1% | 28.1% | 23.4% | 95.2% |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 |
| % Growth | 7.1% | 27.3% | -76.1% | – |
| Operating Cash Flow | $13,293 | $21,139 | -$19,675 | $50,216 |
| Capital Expenditures | -$14,368 | -$2,422 | -$4,701 | -$2,757 |
| Free Cash Flow | -$1,075 | $18,717 | -$24,376 | $47,459 |